Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Hypofractionated versus conventionally fractionated radiation therapy for prostate carcinoma: updated results of a phase III randomized trial.

Yeoh EE, Holloway RH, Fraser RJ, Botten RJ, Di Matteo AC, Butters J, Weerasinghe S, Abeysinghe P.

Int J Radiat Oncol Biol Phys. 2006 Nov 15;66(4):1072-83. Epub 2006 Sep 11.

PMID:
16965866
2.

Evidence for efficacy without increased toxicity of hypofractionated radiotherapy for prostate carcinoma: early results of a Phase III randomized trial.

Yeoh EE, Fraser RJ, McGowan RE, Botten RJ, Di Matteo AC, Roos DE, Penniment MG, Borg MF.

Int J Radiat Oncol Biol Phys. 2003 Mar 15;55(4):943-55.

PMID:
12605972
3.

Hypofractionated versus conventionally fractionated radiotherapy for prostate carcinoma: final results of phase III randomized trial.

Yeoh EE, Botten RJ, Butters J, Di Matteo AC, Holloway RH, Fowler J.

Int J Radiat Oncol Biol Phys. 2011 Dec 1;81(5):1271-8. doi: 10.1016/j.ijrobp.2010.07.1984. Epub 2010 Oct 8.

PMID:
20934277
5.

Stereotactic hypofractionated accurate radiotherapy of the prostate (SHARP), 33.5 Gy in five fractions for localized disease: first clinical trial results.

Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J.

Int J Radiat Oncol Biol Phys. 2007 Mar 15;67(4):1099-105.

PMID:
17336216
6.

Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial.

Arcangeli S, Strigari L, Soete G, De Meerleer G, Gomellini S, Fonteyne V, Storme G, Arcangeli G.

Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):39-45. doi: 10.1016/j.ijrobp.2008.04.005. Epub 2008 Jun 4.

PMID:
18538488
7.

Hypofractionated radiotherapy for favorable risk prostate cancer.

Rene N, Faria S, Cury F, David M, Duclos M, Shenouda G, Souhami L.

Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):805-10. doi: 10.1016/j.ijrobp.2009.05.047.

PMID:
20510194
8.

Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.

Fonteyne V, De Gersem W, De Neve W, Jacobs F, Lumen N, Vandecasteele K, Villeirs G, De Meerleer G.

Int J Radiat Oncol Biol Phys. 2009 Nov 15;75(4):1013-20. doi: 10.1016/j.ijrobp.2008.12.047. Epub 2009 Apr 20.

PMID:
19386427
9.

Hypofractionated boost with high-dose-rate brachytherapy and open magnetic resonance imaging-guided implants for locally aggressive prostate cancer: a sequential dose-escalation pilot study.

Ares C, Popowski Y, Pampallona S, Nouet P, Dipasquale G, Bieri S, Ozsoy O, Rouzaud M, Khan H, Miralbell R.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):656-63. doi: 10.1016/j.ijrobp.2008.11.023. Epub 2009 Feb 26.

PMID:
19250768
10.

Phase II trial of hypofractionated image-guided intensity-modulated radiotherapy for localized prostate adenocarcinoma.

Martin JM, Rosewall T, Bayley A, Bristow R, Chung P, Crook J, Gospodarowicz M, McLean M, Ménard C, Milosevic M, Warde P, Catton C.

Int J Radiat Oncol Biol Phys. 2007 Nov 15;69(4):1084-9. Epub 2007 Jul 2.

PMID:
17606331
11.

Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results.

Lim TS, Cheung PC, Loblaw DA, Morton G, Sixel KE, Pang G, Basran P, Zhang L, Tirona R, Szumacher E, Danjoux C, Choo R, Thomas G.

Int J Radiat Oncol Biol Phys. 2008 Sep 1;72(1):85-92. doi: 10.1016/j.ijrobp.2007.12.041. Epub 2008 Mar 20.

PMID:
18355982
12.

Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy.

Wong GW, Palazzi-Churas KL, Jarrard DF, Paolone DR, Graf AK, Hedican SP, Wegenke JD, Ritter MA.

Int J Radiat Oncol Biol Phys. 2008 Feb 1;70(2):449-55. Epub 2007 Sep 14.

PMID:
17869014
13.

Anorectal function after three- versus two-dimensional radiation therapy for carcinoma of the prostate.

Yeoh EK, Holloway RH, Fraser RJ, Botten R, Di Matteo A, Moore JW, Schoeman MN, Bartholomeusz DL.

Int J Radiat Oncol Biol Phys. 2009 Jan 1;73(1):46-52. doi: 10.1016/j.ijrobp.2008.03.058. Epub 2008 Jun 18.

PMID:
18571336
14.

Comparison of the outcome and morbidity for localized or locally advanced prostate cancer treated by high-dose-rate brachytherapy plus external beam radiotherapy (EBRT) versus EBRT alone.

Fang FM, Wang YM, Wang CJ, Huang HY, Chiang PH.

Jpn J Clin Oncol. 2008 Jul;38(7):474-9. doi: 10.1093/jjco/hyn056. Epub 2008 Jul 11.

PMID:
18621848
16.

Hypofractionated radiotherapy denoted as the "Christie scheme": an effective means of palliating patients with head and neck cancers not suitable for curative treatment.

Al-mamgani A, Tans L, Van rooij PH, Noever I, Baatenburg de jong RJ, Levendag PC.

Acta Oncol. 2009;48(4):562-70. doi: 10.1080/02841860902740899.

PMID:
19373698
17.

Accelerated radical radiotherapy for non-small cell lung cancer using two common regimens: a single-centre retrospective study of outcome.

Pemberton LS, Din OS, Fisher PM, Hatton MQ.

Clin Oncol (R Coll Radiol). 2009 Apr;21(3):161-7. doi: 10.1016/j.clon.2008.11.016. Epub 2008 Dec 25.

PMID:
19111452
18.

Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer.

Yassa M, Fortin B, Fortin MA, Lambert C, Van Nguyen T, Bahary JP.

Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):58-63. doi: 10.1016/j.ijrobp.2007.09.004.

PMID:
18406883
19.

Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial.

Maranzano E, Bellavita R, Rossi R, De Angelis V, Frattegiani A, Bagnoli R, Mignogna M, Beneventi S, Lupattelli M, Ponticelli P, Biti GP, Latini P.

J Clin Oncol. 2005 May 20;23(15):3358-65. Epub 2005 Feb 28.

PMID:
15738534
20.

Reduction of irradiation volume and toxicities with 3-D radiotherapy planning over conventional radiotherapy for prostate cancer treated with long-term hormonal therapy.

Yamazaki H, Nishiyama K, Tanaka E, Maeda O, Meguro N, Kinouchi T, Usami M, Kakimoto K, Ono Y, Nishimura T.

Anticancer Res. 2008 Nov-Dec;28(6B):3913-20.

Supplemental Content

Support Center